News

Coca-Cola Options Trading: What Investors Are Eyeing Now

Coca-Cola Options Trading: What Investors Are Eyeing Now

Current Options Trading Overview for Coca-Cola

Recently, large investors have shown a bearish outlook on Coca-Cola, and this shift is important for retail traders to note.

This insight comes from our analysis of publicly available options data, which has highlighted some significant trades linked to Coca-Cola.

While it’s hard to say whether these trades are purely institutional or from wealthy individuals, such substantial movements can indicate someone might be expecting a major change.

Today, we've spotted some unusual options trades for Coca-Cola that are worth your attention.

Unusual Trading Activity Detected

In particular, our options scanner found 15 unique trades concerning Coca-Cola, which stands out from the normal trading patterns.

Sentiment among these traders is quite divided: about 40% are bullish, while 53% lean towards bearish.

Among the major option strategies, we noted 3 puts, totaling an investment of $235,245, and 12 calls amounting to $851,005, pointing towards a strong interest level.

Coca-Cola’s Price Targets

By examining the volume and open interest of these contracts, it seems that institutional investors are aiming for a price target range of $55.0 to $77.5 for Coca-Cola over the last quarter.

Volume and Open Interest Trends Explained

Volume and open interest are vital metrics in options trading, representing the overall liquidity and interest investors have in Coca-Cola's options at specific strike prices. Analyzing these metrics helps investors understand market trends and behaviors.

Coca-Cola Options Activity: A 30-Day Overview

An analysis of the options trading for Coca-Cola over the past 30 days has shown significant volumes and shifts in open interest. These changes are crucial indicators for adjusting strategies moving forward.

Insights from Recent Options Activity

The following table summarizes key options activity related to Coca-Cola, highlighting aspects like trade type, sentiment, and pricing.

Recent Insights into Coca-Cola Options Activity:

Symbol: KO | Call/Put: CALL | Trade Type: TRADE | Sentiment: BULLISH | Expiration Date: 01/17/25 | Price: $5.40 | Total Trade Price: $232.2K

Symbol: KO | Call/Put: CALL | Trade Type: TRADE | Sentiment: BEARISH | Expiration Date: 12/20/24 | Price: $0.74 | Total Trade Price: $222.0K

Symbol: KO | Call/Put: PUT | Trade Type: SWEEP | Sentiment: BEARISH | Expiration Date: 02/21/25 | Price: $6.45 | Total Trade Price: $167.0K

Symbol: KO | Call/Put: CALL | Trade Type: SWEEP | Sentiment: BEARISH | Expiration Date: 10/11/24 | Price: $16.40 | Total Trade Price: $49.1K

Company Overview: Coca-Cola

Coca-Cola, founded in 1886 and based in Atlanta, is now the largest non-alcoholic beverage company worldwide. With around 200 brands that include sodas, water, sports drinks, energy drinks, juices, and coffee, Coca-Cola works with bottlers and distributors to reach consumers in over 200 countries.

About two-thirds of Coca-Cola's revenue is generated from international markets, especially in rapidly expanding regions like Latin America and Asia-Pacific, showcasing its global reach.

Coca-Cola's Market Position Today

  • Coca-Cola's total trading volume has hit 12,677,698, with shares currently priced at $71.33, reflecting a slight decrease of -0.56%.
  • The Relative Strength Index (RSI) shows that Coca-Cola shares are in a neutral zone, positioned between overbought and oversold levels.
  • Investors are looking forward to an earnings announcement scheduled in 28 days, which may impact trading strategies.

Interested in boosting your investment returns?

A seasoned options trader with twenty years of experience has introduced a unique chart technique aimed at identifying optimal buy and sell opportunities. Learn how he’s achieved an average profit of 27% every 20 days.

Options trading involves considerable risk, and successful investors are those who consistently educate themselves, adapt strategies, and keep a close eye on market indicators. Stay updated on the latest trends in Coca-Cola options trading and receive timely alerts for valuable insights.

Frequently Asked Questions

What recent trends are observed in Coca-Cola options trading?

Recent options trading trends indicate a split sentiment among investors, with the majority leaning towards a bearish outlook.

What are the current price targets set for Coca-Cola stock?

Analysts are targeting trading prices between $55.0 and $77.5 based on recent patterns in trading activity.

How do volume and open interest influence options trading?

Volume and open interest give insights into market liquidity and the collective sentiment of investors regarding specific strike prices.

What is Coca-Cola's current market performance?

Coca-Cola shows a substantial trading volume, with shares recently priced at $71.33, reflecting a slight decline.

Why should investors keep an eye on Coca-Cola's trading movements?

Monitoring Coca-Cola's trading activity can lead to better-informed investment strategies and quicker responses to market changes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading

Top 5 Most Recently Viewed Articles

A Comprehensive Look at Apple's Competitive Position in Tech

Updated Category News Views 313

Understanding Apple's Competitive Landscape In today's dynamic business environment, a deep-dive analysis of top companies is essential for investors and industry insiders. This examination will focus on Apple (AAPL), alongside its chief rivals in the Technology Hardware, Storage & Peripherals sector. By analyzing crucial financial indicators, market positioning, and...

Continue Reading
Cegedim Shares Insights on Latest Liquidity Contract Performance

Updated Category News Views 135

Overview of Cegedim's Liquidity Contract Statement This article covers the latest updates on Cegedim’s liquidity contract performance, highlighting significant figures and trends that reflect the company's financial health. Cegedim has established a robust liquidity contract with Rothschild Martin Maurel, aimed at promoting transparency and liquidity in its shares. Key...

Continue Reading
Silexion Therapeutics Advances SIL204 for Pancreatic Cancer

Updated Category News Views 136

Silexion Therapeutics Moves Forward with SIL204 Silexion Therapeutics Corp. (NASDAQ: SLXN) is celebrating a significant milestone with the completion of crucial toxicology studies for its innovative RNA silencing therapy, SIL204. This groundbreaking therapy, designed to target mutated KRAS oncogenes, has shown no signs of systemic organ toxicity, reinforcing the...

Continue Reading
Emerson Partners with LifeSight for Enhanced Pension Solutions

Updated Category News Views 178

Emerson Partners with LifeSight for Pension Solutions LifeSight, WTW’s UK defined contribution (DC) master trust, has stepped into a significant role by becoming the full master trust provider for Emerson, the advanced electronics powerhouse. This partnership aims to cover all active, deferred, and drawdown members effectively, ensuring they are well-accommodated in...

Continue Reading
Howard Marks Joins Alliance for Decision Education Board

Updated Category News Views 227

Exciting News from the Alliance for Decision Education The Alliance for Decision Education is thrilled to announce an important addition to its Board of Directors. Howard Marks, a leader in investment management and a well-respected voice in decision-making, has agreed to join the board. As the co-chairman and co-founder of Oaktree Capital Management, Marks brings with...

Continue Reading